Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol

16th March 2020

Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for health care professionals in acute care settings compared to traditional nebulisers.

For patients requiring ventilation Aerogen Solo’s vibrating mesh technology and closed-circuit design1 makes it a viable option to help deliver industry-leading care to patients infected with corona viruses, such as COVID-19 .

Recent guidelines from the UK government have stated that when treating respiratory patients2;

1. A closed suctioning system must be used

2. Ventilator circuits should not be broken unless necessary.

Unlike conventional nebulisers, the Aerogen Solo1:

1. Has an in-line circuit design so the ventilation circuit does not need to be broken for drug delivery

2. Is designed so that the medication reservoir is isolated from the breathing circuit minimising nebulisation of contaminated fluids

3. Delivers the medication dose with minimal residual remaining after nebulisation

Aerogen, which is partnered with many of the world’s leading ventilation companies, delivers physician-prescribed medications for inhalation which are approved for use with a general-purpose nebuliser.  In the acute care setting, Aerogen can deliver up to 15% lung deposition3

References 1 Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. 2 Public Health England. Novel coronavirus (2019-nCoV) infection prevention and control guidance. 2020. (accessed 13 Mar2020). 3  Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. Ann Intensive Care 2016; 6: 73. PM659

More News & Events